BioIT Solutions Webinar: Enabling High Efficiency in Translational Science and Medicine


Come watch and listen on how BioIT Solutions has built a COTs platform to handle your toughest late development and translational science/medicine needs by bridging the gaps between science, IT, and business transactional and logistical needs. Whether a small, and/or large molecule, or cell and gene therapy focused company, they have you covered.

Watch Recording Here


BISC Global: Latest Data Analysis Techniques in Biotechnology Through Real-Life Case Studies Webinar

Single-Cell Analysis, Machine Learning & AI, Custom Cloud Environments

BISC Global has 5 offices worldwide (Boston, San Francisco, Belgium, The Netherlands & Switzerland), our expertise in data-analysis, pipeline development and automation, data integration, cloud solutions and biology allow us to provide bioinformatics services of the highest standards. 

Watch Recording Here


BIOVIA Webinar: Timely Batch Release Don’t Let Your QC Labs Slow You Down

Many Quality Control (QC) laboratories in pharma- and biomanufacturing have not yet achieved digital transformation yet. In fact, many are still using paper and basic generic tools. This leads to cumbersome and time-consuming quality testing. Sampling and test execution, data entry and review, reporting and documentation, approval and certification—QC Labs need to accomplish all these steps according to defined procedures and in compliance with regulations. It is impossible to do so efficiently without a true digital system.


True digitalization—connecting people, processes, and data together—is the best way to improve productivity and enhance regulatory compliance. Open, platform-based solutions enable standardization, data aggregation through common models, and integrated analytics and visualizations. In this webinar our panel of experts will articulate a realistic and achievable vision for QC labs that will help increase productivity for timely batch release while improving data integrity and regulatory compliance.

Watch Recording Here


Zifo Mega LIMS Webinar Series #6: Lessons Learnt from Global Rollouts of LIMS - Harmonization and Validation

Zifo R&D Solutions and 20/15 Visioneers are announcing the Live Mega LIMS Webinar Series for 2021. In this approximately 14 webinar series we will bring you a highly educational overview webinar followed by topic-driven LIMS webinars.

Watch Recording Here


PerkinElmer, KML Vision, Altis Labs & Confocal Webinar: Imaging and the Incredible Impact on Science

Imaging is one of the most exciting and fast-evolving fields in science today. These diverse companies are making a huge impact across the drug discovery continuum.

In the cellular space, “seeing is believing” started with the advent of fluorescent proteins and now genetic markers and microscopy technology have enabled a deeper understanding of cellular architectures. Techniques such as cell painting and high-content screening are making huge impacts. What is more amazing than visualizing diverse proteins interacting to trigger signaling cascades? Incredibly advanced yet user-friendly microscopes provide a whole new perspective (no pun intended!) into wound healing, cytotoxicity, cell cycle, and cell death, among many other cellular processes. The combination of microscopy and other techniques, including AI/ML approaches, opens new avenues of research to characterize novel mechanisms and drugs in all kinds of primary cell types and cell lines.

In the clinical arena, radiological and pathological imaging have seen an explosion of novel tools that offer diagnostic, prognostic, predictive, and monitoring insights. While imaging has been used for decades in clinical trials, its interpretation was historically limited by arbitrary criteria like RECIST. Now, scientists have the capability to capitalize on the full breadth of pixel data and automatically derive quantitative, reproducible measures using deep learning and computer vision. Imagine being able to give researchers twice as accurate a measure of treatment effect, or arming a clinician with actionable insights that let them personalize treatment for the patient in front of them!

This webinar will feature four companies that are disrupting the way we look at our cells and anatomy with innovative technologies and solutions. Learn how Altis Labs, Confocal.nl, KML Vision, and Perkin Elmer are advancing our understanding of biological processes to accelerate therapeutic development!

Watch Recording Here


OriCiro- Cell Free DNA Technology for Synthetic Biology

Looking for a better way to handle some of your DNA technology and science? OriCiro has developed an innovative and Best-In-Breed DNA technology that has overcome challenges in the development of vaccine, cell, and gene therapies! This webinar is all about OriCiro and how its technology can drive much better outcomes for your molecular and synthetic biology!

Watch Recording Here


Zifo Mega LIMS Webinar Series #5

Another knowledge-sharing opportunity for optimizing your ELN/LIMS environment! Hear from experts on best practices when it comes to data, services, application, and cloud integrations! On-Prem to Cloud, Cloud to Cloud, and enterprise integration environments.


Zifo R&D Solutions and 20/15 Visioneers are announcing the Live Mega LIMS Webinar Series for 2021. In this approximately 14 webinar series we will bring you a highly educational overview webinar followed by topic-driven LIMS webinars. The first three webinars discussed experiences, best practices, and some theories.  In this webinar, we will be showing tools and techniques that we use to do business process mapping, requirements gathering, vendor market analyses, and then the managing of an implementation. Hear about the processes and exceptions that will keep you on track to delivering a successful ELN, LIMS, LIS, LES, etc. solution!  


Watch Recording Here



Strateos & PerkinElmer: Cloud Lab: Remote Access Robotic Controlled Compound Synthesis

Strateos, a pioneer in the development of remote access laboratories and lab control software for life science research, has expanded its chemistry solutions by integrating with the PerkinElmer Informatics Signals™ Notebook electronic lab notebook. The combined platform enables small molecule compound design and synthesis, and purification workflows. By supporting early lead generation, chemists are able to quickly explore synthesis and structure-activity relationship (SAR) studies around selected scaffolds and efficiently progress to the next round of synthesis and screening.


The combined platform integrates chemistry and biology and as a result scientific organizations now have access to a variety of new technologies that offer faster cycle times than traditional labs.

The webinar will reveal the following:


  • Strateos' remote access fleet of lab automation modules, speeds the design-make-test-analyze cycle and generates clean, AI-enabled data.

  • On-demand automated compound synthesis and purification workflow support early lead generation phases when chemists want to quickly explore synthesis and support structure-activity relationship (SAR) studies.

  • The integration of the PerkinElmer Signals Notebook with Strateos’ powerful automated synthesis system facilitates the efficient synthesis of drug-like compounds

  • How leading scientific organizations use the Strateos SmartLab Platform™ for robotically controlled compound synthesis.



Watch Recording Here



TetraScience: Oh, the Places You’ll Go!” How the integration of cloud-native platforms and ELNs are Fueling Innovation in R&D

ELNs, (Electronic Lab Notebooks), are important tools in scientific workflows and play a fundamental role in the Lab of the Future. These systems capture experimental results, manage sample provenance and logistics, and allow iteration on the Design, Make, Test, Analyze (DMTA) loop.


Pairing ELNs together with cloud-native, data-centric solutions that automate the entire data life cycle — collection, centralization, harmonization, enrichment, export — allows researchers to benefit from seamless, end-to-end R&D data flow. Researchers quickly optimize experimental design and execution, validate experimental results, and accelerate discovery from the insights into the data while maintaining high data integrity and process reproducibility.


Join this interactive panel discussion and Q&A with TetraScience Chief Scientific Officer, Mike Tarselli, Ph.D., MBA and IDBS VP of Business Development and Open Innovation, Scott Weiss, Ph.D. to learn how ELN systems, paired with the Tetra Data Platform (TDP) facilitates:


  • Turn-key integration of ELN systems with a cloud-native platform fosters and future-proofs a community built on data liquidity

  • The adoption of FAIR data principles and processes and frictionless access to data

  • Streamlined documentation of experiments, while easily keeping track of and/or creating entities

  • Significant time-savings to organizations and researchers and allows them to focus on drug discovery


Watch Recording Here 



OpenBench: A Results-Driven Paradigm in Structurally-Enabled Hit Discovery

For decades discovery organizations have paid for technology without the guarantee of tangible results. OpenBench is turning this business model on its head––with OpenBench you can screen billions of compounds and only pay for experimentally validated hits.

OpenBench combines virtual screening techniques with powerful parallel synthesis and blazingly efficient machine learning-enabled chemical space search to enable an unprecedented value proposition in small molecule hit discovery. Unlike conventional hit ID approaches that incur hundreds of thousands or even millions of dollars in upfront costs without the sure promise of success, with OpenBench, you bear no cost risk in hit discovery. By covering the full, actual cost of virtual screening, putative hit synthesis, and confirmatory assaying, OpenBench ensures that you only pay for results: a novel, potent hits that meet your develop-ability criteria.


To learn more about how you can enrich your preclinical discovery efforts with results-driven hit discovery, join OpenBench CSO Lewis Martin, Ph.D., and OpenBench CTO James Yoder.


Watch Recording Here


Zifo Mega LIMS Webinar Series #4 The HOW: Tools and Techniques Used for Success


Zifo R&D Solutions and 20/15 Visioneers are announcing the Live Mega LIMS Webinar Series for 2021. In this approximately 14 webinar series we will bring you a highly educational overview webinar followed by topic-driven LIMS webinars. The first three webinars discussed experiences, best practices, and some theories.


In this webinar, we will be showing tools and techniques that we use to do business process mapping, requirements gathering, vendor market analyses, and then the managing of an implementation. Hear about the processes and exceptions that will keep you on track to delivering a successful ELN, LIMS, LIS, LES, etc. solution!

Watch Recording Here


Elucidata's Liver OmixAtlas: The World's Most Comprehensive & Curated Liver Tissue-Derived Data

Every year, vast amounts of biological multi-omics data are being generated in academic labs and organizations worldwide. This data holds tremendous potential for reuse but is scattered across multiple, disparate sources and lacks standardization. Thus, the availability of data does not equate to its easy usability, making the need for an efficient means of exploring molecular data an immediate necessity.

Additionally, biological systems and processes are intrinsically complex. No single data type, be it metabolomic, proteomic or genomic, will be sufficient to capture the complexity of biological phenomena. Adopting an integrated approach could significantly aid the ability to gain a holistic and more accurate understanding of physiology and disease pathology at the molecular level.

Elucidata’s Liver OmixAtlas, the largest, multi-omics data repository of liver tissue-derived data, aims to address these issues. It contains FAIR molecular data (Genomics, Transcriptomics, Proteomics, and Metabolomics) from various public sources, encompassing normal as well as perturbed (disease, drug treatment, gene knockouts/down, etc.) states of liver tissue. Adherence to FAIR principles ensures that the curated data is harmonized and ML-ready. In keeping with the rapid pace of biological data generation, OmixAtlas is updated with a frequency that is in sync with the source repositories.

Data integrability is another key feature of OmixAtlas. FAIR data enables any number of harmonized omics data to be integrated and analyzed, thereby enriching the process of data exploration and insight discovery. In addition to publicly available data, proprietary data can also be analyzed with customized workflows on our cloud-based platform, Polly. Polly’s cloud infrastructure enables seamless data analysis, visualization and sharing by offering a toolbox of scalable, easy to customize, bioinformatics pipelines. Liver OmixAtlas, thus, will accelerate the process of deriving unique insights.  

Watch Recording Here


TetraScience: Why Life Sciences R&D Organizations are Re-platforming Their Experimental Data to the Cloud

Are you struggling with an inordinate amount of data wrangling, technology, and operational silos, and slow progress on your digital transformation journey? You’re not alone. Many R&D organizations suffer from fragmented, heterogeneous experimental data, legacy on-prem instrumentation, and systems, and outdated workflows that impede discovery and innovation. However, a movement is underway to re-platform experimental data to the cloud, and accelerate discovery before it’s too late and the opportunity window closes.

TetraScience is leading the data re-platforming movement in the life sciences R&D industry by leveraging cloud-native technology to break down silos and remove bottlenecks in traditional lab workflows. With bidirectional data integration, the Tetra Data Platform (TDP) automates the full life cycle of R&D data: acquisition, harmonization, engineering, AI/ML enrichment, and continuous experimentation.

Join Mike Tarselli, Ph.D., MBA, and Chief Scientific Officer at TetraScience, for a webinar on June 22, 2021, at 11 am ET, where you’ll learn:

  • How a network of productized integrations between data sources and targets eliminates the burden of costly point-to-point integrations and manual data wrangling.

  • Why re-platforming data to the cloud is an essential first step in making it FAIR: Findable, Accessible, Interoperable, and Reusable.

  • What are the top use cases for bidirectional data integration in R&D, and what are their benefits? 

Watch Recording Here


Zifo Mega LIMS Webinar Series #2

Zifo R&D Solutions and 20/15 Visioneers are announcing the Live Mega LIMS Webinar Series for 2021. In this approximately 14 webinar series we will bring you a highly educational overview webinar followed by topic-driven LIMS webinars.

Watch Recording Here


Zifo Mega LIMS Webinar Series #1

Zifo R&D Solutions and 20/15 Visioneers are announcing the Live Mega LIMS Webinar Series for 2021. In this approximately 14 webinar series we will bring you a highly educational overview webinar followed by topic-driven LIMS webinars. In our first overview webinar of the series, we will focus on these topics:

  • Hybrid ELN-LIMS Platform Approach That Can Actually Handle the Work

  • Mobility and Remote working – IoT + Edge computing

  • R&D – what makes a good LIMS – are they too rigid, can they help, how much can be done in ELN

  • Manufacturing and QC

  • COTS vs Customizations

  • Clear, Concise, and Configurable Requirements

  • Legacy Data Migration

  • Cost of Ownership and Support

The follow-on LIMS webinars will include (and may not be limited to) the following topics:

  • How to gather requirements for LIMS selection and deployment

  • Security, Migrations, Cloud vs On-Prem, and Master Data

  • Lab Operations

  • Sample Analytical Processing

  • LIMS Integration Best Practices

  • Maximizing Data Value – Longevity of the system

  • Bioanalytical and Formulations

  • Total Management and Support

  • Manufacturing QC

  • Clinical & BioBanking

  • Chemical - Materials Science + Formulations

  • Consumer Goods & Food

  • Forensics

Watch Recording Here


Companies Making BIG Impacts in Computational Chemistry and Approaches

20/15 Visioneers will be presenting 4 Computational Chemistry Oriented companies that are making big impacts in Drug Discovery! In the marketplace today, Discngine ( https://www.discngine.com ), Nanome (https://www.nanome.com ), OpenEye Scientific Software (https://www.openeye.inc ), and XtalPi (https://www.xtalpi.com ). The format will be a brief overview from John F. Conway and then each company will spend 20 minutes presenting their platform overview. We will then go into Q&A mode with the vendor-partners and industry panelists. This innovative approach will allow an introduction to companies you may not be familiar with, and provide you with a very good understanding of their offerings! The types of criteria that we looked for when assembling this list were platform approach, scientific innovation and domain coverage (ISDMTAR), configurability, data management, FAIR compliance, and intuitiveness/usability. Background talk by 20/15 Visioneers, 20 Minute presentations, and then Q&A with industry panelists and Partner-Vendors!

Watch Recording Here


Molecular Biology Enabled ELN+ Platforms

Molecular Biology is a critical part of Drug and Therapy Discovery today. With thousands of documented techniques, what is the best platform or scientific software environment to capture, document, and reuse molecular biology data and processes? What are the foundational offerings? Biological Entity Registration, DNA, RNA, Protein, lipid engineering tools? New modality capabilities? We will be hosting a webinar, giving a historical overview, and hosting Four Scientific Software and Platform companies that evolved advanced molecular biology tools within these powerful environments: Arxspan (www.arxspan.com), Benchling (www.benchling.com), Perkin Elmer (www.perkinelmer.com), and Sapio Sciences(www.sapiosciences.om) will provide their current and near future capabilities.

Watch Recording Here


Making HTE Easier and More Accessible to Scientists

The benefits of high throughput experimentation cannot be overstated. In R&D organizations, where trial & error is a part of a scientist’s everyday life, nothing can be better than having the ability to test multiple knowledge-driven hypotheses simultaneously. Yet, there are still many lab-based chemists that will serially test their synthetic hypotheses (new transformations, reactivity, solvent effects, etc), often over-stressing how the results of each experiment will provide important learnings for future iterations. While this is arguably true, a well-designed array of carefully controlled experiments, will almost always supply you with improved conditions for a specific transformation, and usually faster than any serial journey of single reactions. So, if that is true, more often than not, then why do researchers resist efficiency and reproducibility and default to what is familiar - serial experiments? One simple answer is basic human behavior - our aversion to change.

For change to occur in any organization, there must be a demonstrable benefit to the individual scientist, as well as the collective organization, but maybe more important than that, the cost of change, cannot exceed the benefit to those being asked to change their work routines. In this case the cost to those making the changes is perceived and real, as measured by personal frustration and by temporary productivity loss during the sometimes-unavoidable transition period. Lowering the cost of this change by simplifying the integration and adoption of semi-automated and automated kit, and improved software to easily orchestrate and capture experimental results into daily workflows, is a paramount objective for both software and hardware suppliers.


In this webinar suppliers ACD/Labs (https://www.acdlabs.com), Chemspeed Technologies (https://www.chemspeed.com), ILS (https://www.integratedlabsolutions.com), and Sapio Sciences(www.sapiosciences.om) will describe their efforts to simplify acceptance so that, when appropriate, high throughput experimentation becomes the default choice for scientists! 

Watch Recording Here


LeapYear, the Most Compelling Data Privatization Company for R&D

In today’s highly complex Biopharmaceutical Research and Development Environment, Data is the common entity that drives Ideation, Simulation, Design, Synthesis, Analysis, and further Integrated Decision making.  These highly complex data-driven organizations are challenged by not only the types of data (RCT, RWE, Omics) but the origin of data and the right to use this data (consent) in various scenarios, further complicated by geographical barriers or rules.  For years organizations and groups have relied on data anonymization to prevent data origin or any potential personal details from being known.  Simply put, this does not meet today's security criteria.  LeapYear  (https://leapyear.io) has developed algorithms that not only ensure data privacy but also enable model quality data for use in machine learning. 

The combination of regulatory frameworks (GDPR) and public perception makes ensuring proper use/handling of this data a strategic priority.  However, leadership must balance the governance costs (time, restricting access, duplication of effort, removing info) with the validity/usefulness/timeliness of the data. 

We will discuss several high-value use cases that are enabled by implementing a new data exchange/sharing/access model based on LeapYear: 


  • Working with sensitive data assets like RWE and Genomic data across teams and geographic boundaries.  Key outcome: enabling more teams to have more access to data, faster, and with full fidelity 

  • Third-party data acquisition - helping teams both deal with the data they already acquire (in a more valuable, more private way) and helping them get access to more data (e.g. from healthcare providers) that may be impossible to get access to without a mechanism like differential privacy.   

  • Crossing lines of business - R&D teams can be broken into specialty areas, and therefore hard to share data across lines. But this data could be used to drive initiatives across lines.  Commercial teams are often restricted from seeing much of the data from the R&D side, but this data may be useful to analyze real outcomes in the world and drive important analysis like market share, customer churn, prescription trends, etc.  Key outcome:  enabling the pharma, across all teams, to fully leverage their data assets. 

Watch Recording Here


The Most Disruptive and Compelling Automated Biology Companies of 2020

Automated Biology Companies Driving Massive R&D Efficiency Gains

High Throughput Experimentation (HTE) in the modern biology lab is as critical as in any other aspect of R&D, as well as absolutely essential to improve productivity in drug discovery. HTE Biology brings quality, automation and biological and technical innovation as the underpins of plurality and speed in modern drug discovery. This concept applies to assay development and screening systems, biochemical and cell-based assays, detection technologies (e.g., qRT-PCR, flow cytometry, immunoassays, high content imaging) and much more. Among exciting new technologies, gene editing, cellular engineering and synthetic biology emerge to the top as drivers of innovation and change in the way we do drug discovery and development. This webinar will feature four companies that are disrupting the way we do biology with outstanding innovative technologies and solutions. Come and hear about what https://www.berkeleylights.com/, https://highresbio.com/, https://kytopen.com/, and www.Synthace.com, are doing to bring the Lab of the Future to reality via lab automation, computer-aided biology, robotics, synthetic biology, cell engineering, new technologies to develop cell-based therapies, and more. 

Watch Recording Here


A Next-Generation Multi-Omics Example Blue Print

The Omics (Genomics, Transcriptomics, Proteomics, Epigenomics, Metabolomics, and more) space has exploded over the past 10 years and like many other newer or advanced scientific and technological approaches there have been many lessons learned. One is you are going to need an enhanced scientific data management environment! As these data and experiences are driving more, and hopefully better decision making, it has become necessary to take these environments to the next software, workflow, and FAIR data/process solution space.

We are working closely with global R&D companies to ensure they have thought through their needs for a scalable multi-omics infrastructure.
In this webinar, we are covering companies that bring Best-in-Breed capabilities from the perspective of the 6 basic workflows: Request, Sample, Test, Experiment, Reporting, and Analysis. FAIR data and processes are a prerequisite as insilico and secondary use of data is part of the mission. Join us for a 20/15 Visioneers overview and then presentations from Genestack, Sapio Sciences, and Titian, and maybe one more surprise Partner-Vendor. 

Watch Recording Here